हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।
ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं
Diane Craciun
Triple negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expressions. Tumor-infiltrating lymphocytes (TILs) play a crucial role in the immune response against TNBC, potentially influencing disease progression and treatment outcomes. This study investigated whether the presence and distribution of TILs in TNBC are affected by BRCA gene alterations, given the potential implications for immunotherapy and treatment strategies. We conducted a retrospective analysis of TNBC cases, categorizing them into two groups: those with BRCA gene alterations and those without. We assessed the quantity and spatial distribution of TILs within tumor samples using immunohistochemistry and analyzed the clinical characteristics of the patient cohorts. The results of this study reveal that the amount and organization of TILs in TNBC remain largely unaffected by BRCA gene alterations. There was no significant difference in TIL density or distribution between the two groups. These findings suggest that the immune microenvironment in TNBC is primarily driven by tumor-specific factors and characteristics of the tumor microenvironment, rather than BRCA gene status. This study contributes to our understanding of the immune response in TNBC and underscores the need to explore alternative strategies to enhance immunotherapy efficacy in this aggressive breast cancer subtype. Further research is required to identify factors influencing TIL recruitment and activation in TNBC, ultimately leading to improved treatment approaches for this challenging disease.